- Acquisition of IFM Therapeutics subsidiary gives Novartis full rights to one clinical and two pre-clinical NLRP3 antagonist programs
- NLRP3 inhibition offers novel approach to preventing chronic inflammation that drives serious disease
- IFM to receive $310 million upfront, with up to $1.265 billion in milestones for a total of $1.575 billion